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INTRODUCTION

RESULTS & DISCUSSION

Reperfusion injury is the acceleration of heart damage which occurs
during the reintroduction of coronary blood flow to a prolonged ischemic
area [1]. Oxidative stress is a major cause of reperfusion injury by
reducing the bioavailability of nitric oxide (NO), damaging cellular
function leading to cell death/apoptosis. To date, there is no effective
clinical treatment for reperfusion injury. CAPE is an active component of
propolis collected from honeybee hives that exhibits both anti-oxidant
and anti-inflammatory effects [2]. Recently, CAPE when given prior to
ischemia was found to be cardioprotective against I/R injury [3,4]. The
beneficial effects of CAPE are possibly mediated by upregulating heme
oxygenase-1 and/or increased bioavailability of NO. However, the effects
of CAPE when given at reperfusion in myocardial I/R (MI/R) injury has
not been evaluated. This study tested the effects of CAPE on
postreperfused cardiac function, infarct size, and putative mechanisms in
an isolated rat MI/R model when given at reperfusion.
Figure 1. Chemical structure
of CAPE. Adapted from
Murtaza et al, 2014.
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CAPE (n=5) restored LVDP to 85 ± 14% of baseline value at 60 min
post-reperfusion compared to untreated control I/R hearts (n=11) that
only recovered to 45 ± 8% of baseline value (p<0.01).
CAPE (n=5) restored LVESP to 139 ± 14% of baseline value at 60 min
post-reperfusion compared to untreated control I/R hearts (n=11) that
only recovered to 106 ± 7% of baseline value (p<0.05).
CAPE (n=5) restored dP/dtmax to 60 ± 11% of baseline value at 60 min
post-reperfusion compared to untreated control I/R hearts (n=11) that
only recovered to 33 ± 5% of baseline value (p<0.05).
CAPE (n=5) also significantly reduced infarct size to 19 ± 2%
compared to 37 ± 3% in untreated control I/R hearts (n=11) (p<0.05).

Figure 3. Time course of LVDP (Difference between LVESP and
LVEDP) for Control I/R, I/R + 40 μM CAPE, I/R + 40 μM CAPE + 50
μM L-NAME, and I/R + 40 μM CAPE + 20 μM SnPP groups. (* p<
0.05, ** p< 0.01 vs. I/R; ##p< 0.01 vs. I/R + 40 μM CAPE)

Figure 4. Time course of dP/dtmax (maximal rate of left ventricular
systolic pressure over time) for Control I/R, I/R + 40 μM CAPE, I/R + 40
μM CAPE + 50 μM L-NAME, and I/R + 40 μM CAPE + 20 μM SnPP
groups. (* p< 0.05, ** p< 0.01 vs. I/R; # p<0.05, ##p< 0.01 vs.
I/R + 40 μM CAPE)

HYPOTHESIS

A non-selective nitric oxide synthase inhibitor, L-NAME (50 µM, n=5);
or a heme oxygenase-1 inhibitor, SnPP (20 µM, n=5), significantly
abolished the cardioprotective effects of CAPE (all p<0.05).

CONCLUSION

In this study, we hypothesized that CAPE when given at reperfusion
would attenuate I/R induced cardiac contractile dysfunction and infarct
size. Moreover, the cardioprotective effects of CAPE would be inhibited
by a non-selective NO synthase inhibitor (NG-nitro-L-arginine methyl
ester (L-NAME)) or a heme oxygenase-1 inhibitor (tin protoporphyrin
(SnPP)).

Our results suggest that CAPE when given at reperfusion improves postreperfused contractile function and reduces infarct size. The
cardioprotective effects of CAPE may be mediated by increasing NO
bioavailability and/or heme oxygenase-1 activity. The effects of CAPE on
mitochondrial function during I/R will be determined in future experiments.

METHODS
Isolated Rat Heart MI/R Experiments: Hearts were isolated from male
Sprague Dawley rats (275-325g, Charles River, Springfield, MA) via
Langendorff heart preparation as previously described [5]. Experimental
protocol is shown in Figure 2.
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